My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 289

    1.

    Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.

    Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A.

    Diabetes. 2008 Feb;57(2):325-31. Epub 2007 Nov 8.PMID: 17991759 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

    Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.

    Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. Epub 2006 Jan 10.PMID: 16403774 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

    Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

    Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

    Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

    Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C.

    J Clin Endocrinol Metab. 2006 May;91(5):1916-23. Epub 2006 Feb 21.PMID: 16492694 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

    Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.

    Regul Pept. 2004 Apr 15;118(1-2):89-97. Erratum in: Regul Pept. 2005 Nov 15;131(1-3):111. Gallwitz, J Baptist [corrected to Gallwitz, Baptist]. PMID: 14759561 [PubMed - indexed for MEDLINE]Related articles

    7.

    No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans.

    Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S, Paulson OB.

    Diabetes. 1999 Oct;48(10):1915-21.PMID: 10512354 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.

    Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D.

    Diabetes Care. 2003 Mar;26(3):837-42.PMID: 12610046 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia.

    Segel SA, Fanelli CG, Dence CS, Markham J, Videen TO, Paramore DS, Powers WJ, Cryer PE.

    Diabetes. 2001 Aug;50(8):1911-7.PMID: 11473055 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.

    Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt WE, Meier JJ.

    Regul Pept. 2007 Oct 4;143(1-3):64-8. Epub 2007 Mar 20.PMID: 17434608 [PubMed - indexed for MEDLINE]Related articles

    11.

    Glucagon-like peptide 2 inhibits ghrelin secretion in humans.

    Banasch M, Bulut K, Hagemann D, Schrader H, Holst JJ, Schmidt WE, Meier JJ.

    Regul Pept. 2006 Dec 10;137(3):173-8. Epub 2006 Aug 22.PMID: 16928403 [PubMed - indexed for MEDLINE]Related articles

    12.

    The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.

    Zander M, Madsbad S, Deacon CF, Holst JJ.

    Diabetologia. 2006 Feb;49(2):369-74. Epub 2005 Dec 30.PMID: 16385384 [PubMed - indexed for MEDLINE]Related articles

    13.

    Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

    Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA.

    Diabetologia. 2006 Mar;49(3):452-8. Epub 2006 Jan 31.PMID: 16447057 [PubMed - indexed for MEDLINE]Related articles

    14.

    Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.

    Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ.

    Gastroenterology. 2006 Jan;130(1):44-54.PMID: 16401467 [PubMed - indexed for MEDLINE]Related articles

    15.

    Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

    Kastin AJ, Akerstrom V, Pan W.

    J Mol Neurosci. 2002 Feb-Apr;18(1-2):7-14.PMID: 11931352 [PubMed - indexed for MEDLINE]Related articles

    16.

    Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans.

    Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA, Krakoff J.

    Neuroimage. 2007 Apr 1;35(2):511-7. Epub 2007 Jan 18.PMID: 17317222 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

    Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

    Diabetologia. 2008 Apr;51(4):632-40. Epub 2008 Feb 22.PMID: 18292985 [PubMed - indexed for MEDLINE]Related articles

    18.

    Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action.

    Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Zheng D, Bergman RN.

    Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E779-85. Epub 2006 May 23.PMID: 16720628 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.

    Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C.

    Digestion. 2006;73(2-3):142-50.PMID: 16809911 [PubMed - indexed for MEDLINE]Related articles

    20.

    Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.

    Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD.

    Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E380-4. Epub 2007 Dec 4.PMID: 18056788 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity